Portal hypertension (PHT) is a common complication of liver cirrhosis and significantly increases morbidity and mortality. Abrogation of PHT using NSAIDs has demonstrated that prostacyclin (PGI 2 ), a direct downstream metabolic product of cyclooxygenase (COX) activity, is an important mediator in the development of experimental and clinical PHT. However, the role of COX isoforms in PGI 2 biosynthesis and PHT is not fully understood. Methods: Pre-hepatic PHT was induced by portal vein ligation (PVL) in wild-type, COX-1 -/-and COX-2 -/-mice treated with/without COX-2 (NS398) or COX-1 (SC560) inhibitors. Hemodynamic measurements and PGI 2 biosynthesis were determined 1-7d after PVL or sham surgery. Results: Gene deletion, or pharmacological inhibition of COX-1 or COX-2 attenuated but did not ameliorate PGI 2 biosynthesis after PVL or prevent PHT. In contrast, treatment of COX-1 -/-mice with NS398 or COX-2 -/-mice with SC560 restricted PGI 2 biosynthesis and abrogated the development of PHT following PVL. Conclusion: Either COX-1 or COX-2 can mediate elevated PGI 2 biosynthesis and the development of experimental pre-hepatic PHT. Consequently, PGI 2 rather then COX selective drugs are indicated in the treatment of PHT. Identification of additional target sites downstream of COX may benefit the >27,000 patients whom die annually from cirrhosis in the US alone.
INTRODUCTION
In the United States cirrhosis and chronic liver disease is the 12 th leading cause of death and in 2005 accounted for more than 27,000 deaths.(60) Portal hypertension is a serious complication of liver cirrhosis, whereby increased resistance to portal flow is almost always the initial pathophysiologic event and is followed by an increased portal venous flow through a hyperdynamic splanchnic system.(46) Increased portal venous pressure promotes the formation of collateral venous circulation and esophageal and gastric varices.(55) These events impart a significant increase in mortality and morbidity via a propensity for variceal hemorrhage and encephalopathy.(5) About 25-40% of all cirrhotic patients have varices of which 1 / 3 rd will hemorrhage with a 20-30% mortality rate.(33) In the absence of liver transplantation the current, recommended treatment for PHT and variceal formation are -blockers to reduce heart rate and portal venous flow, variceal banding and transhepatic intrajugular portal shunts.(18, 27) However, these treatment schemes do not focus on the underlying etiology that increases portal venous pressure. In particular, they do not address the aberrations in systemic and splanchnic circulation that promote increased portal flow and increased portal venous pressure. A cohort of studies have shown that over expression of prostacyclin (PGI 2 ) reduces systemic and splanchnic resistance and the resultant increased flow is key to increased portal venous pressure. (7, 22, 48, 59) PGI 2 is a potent vasodilator and anti-thrombotic agent and is a member of the prostanoid family. The biosynthesis of prostanoids, which include the prostaglandins and thromboxane, occurs in three steps: (a) the mobilization of arachidonic acid, from membrane phospholipids through the action of phospholipase A 2 ; (b) the formation of prostaglandin endoperoxide H 2 (PGH 2 ) via prostaglandin endoperoxide H synthase (PGHS); and (c) the conversion of PGH 2 to specific prostanoids through the action of a synthase such as PGI 2 synthase to form PGI 2 . There are two PGHS isoforms that have similar enzymological and structural properties. These are commonly referred to as cyclooxygenase enzymes or COX-1 and COX-2 ( Figure 1 ).(50, 51) Therefore, as COX-1 and -2 catalyze the first committed step in the production of PGI 2 nonsteroidal antiinflammatory drugs (NSAIDs), which inhibit prostaglandin biosynthesis, should limit PGI 2 biosynthesis and the development of PHT. Indeed, PHT can be abrogated in rats and rabbits by reducing PGI 2 levels following the blockade of COX activity with the NSAID indomethacin. (7, 15) . Unfortunately, gastric ulceration is a serious complication associated with the use of NSAIDs.
Until recently the maintenance of gastric mucosal integrity was believed to be dependant upon COX-1 derived protective PGE 2 from gastric and duodenal epithelium.(24, 47, 57) In contrast, under normal physiological conditions PGI 2 biosynthesis is believed to be mediated by COX-2. (11, 36) This diversity argued that COX-1 and -2 have distinct functions in tissues and organs and that selective inhibition of COX isoforms may have useful therapeutic outcomes. Animal models and clinical studies have shown that COX-2 inhibitors do not induce gastric ulcers. (35) Consequently, it was hoped that this new class of drug could be beneficial in the acute treatment of PHT. However, since then, COX-2 inhibitors have been further studied leading to the withdrawal of rofececoxib (Vioxx) and valdecoxib (Bextra). (10) While, celecoxib (Celebrex) remains available albeit with an FDA mandated boxed warning.
Despite the increased risks, the biological basis for the cardiovascular consequences of COX-2 inhibition continues to be elucidated and research in to COX-2 inhibitors and COX enzymology persists. (14, 16, 20, 35, 62) In particular, two recent publications into the gastrointestinal advantages of COX-2 inhibitors shows that the role of COX inhibitors are still relevant and as such the role of COX isoforms in PGI 2 biosynthesis and PHT is significant. (2, 32 ) Previous experimental models investigating PGI 2 biosynthesis in PHT have been inconclusive. Increased levels of COX-1 and -2 in the aorta and mesenteric vascular bed of portal vein ligated (PVL) rats suggest no isoform preference.(2, 32) Conversely, Tsugawa et al. (1999) have shown that NS398, a COX-2 specific inhibitor, prevented PHT in PVL rats.(42) Moreover, pharmacological studies can sometimes be misleading. For example, 1) COX-1 gene deleted mice have no gastric pathology and are resistant to indomethacin induced gastric ulceration.(28) 2) selective inhibition of COX-1 in healthy rats with SC560 does not induce gastric ulcers (19, 56) 3) COX heterodimers are resistant to COX isoform selective inhibition (62) 4) Both COX-1 and COX-2 contribute to increased PGI 2 in non PHT vascular disorders.(4) Therefore, the COX isoform profile associated with elevated PGI 2 in PHT is not clear and a better understanding is required.
To address which COX isoform is essential to the development of PHT we utilized a murine prehepatic PVL model of PHT in wild type and COX-1 -/-and COX-2 -/-mice. Within this study we investigate the effect of (1) selective inhibition of COX-2 (NS398) or COX-1 (SC560), (2) the targeted gene deletion of either COX-1 or COX-2 and (3) a combination of targeted COX isoform gene deletion with pharmacological COX inhibition (COX-1 -/-± NS398 or SC560 or COX-2 -/-± SC560 or NS398) on PGI 2 levels, abdominal aortic flow (systemic hyperemia) or splenic pulp pressure following PVL. This data will improve our understanding of PGI 2 biosynthesis and therapeutic targets needed to benefit cirrhotic patients at risk of PHT and variceal hemorrhage.
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EXPERIMENTAL PROCEDURES
Pre-hepatic PHT model; Partial portal vein ligation
All studies are approved by the Indiana University institutional animal care and use committee and adhere to AAALC and federal guidelines for the humane care and treatment of animals. Mice were maintained in sterilized isolette cages on a 12-hour light/dark cycle and were allowed access to food and water ad libitum. Mice were anesthetized using halothane inhalation. A midline laparotomy was performed and the portal vein was exposed. A blunt-ended 27-gauge needle was placed alongside the portal vein and a 4-0 silk suture was tied around the vein and needle, after which the needle was withdrawn, producing a standardized stenosis. In sham animals the procedure consisted of dissection and visual inspection of the portal vein without ligature. The abdomen was closed and the animals were allowed to recover under a heat lamp.
Physiological measurements
Physiological measurements were performed as previously described by Theodorakis et al. 2003.(54) At the indicated times post sham-operation or PVL, animals were anesthetized and subjected to laparotomy to allow physiological measurements to be taken. Portal pressure was determined by measuring the splenic pulp pressure. We have previously shown that portal venous pressure and splenic pulp pressure are directly proportional.(54) To measure splenic pulp pressure a micro-tip pressure transducer (SPR-839, Millar Instruments, TX) was inserted in the spleen. Aortic flow (Qao) was measured by placing an ultrasonic Doppler flow probe (Transonic #11RB) around the abdominal aorta between the diaphragm and celiac artery. Flow rates were obtained with a Transonic T206 Blood Flow Meter (Transonic Instruments, Ithaca, NY). Aortic blood flows were standardized per gram of body weight.
Gene-deficient mice
Mice containing targeted mutations in prostaglandin H synthase (ptghs)-1 gene (COX-1; strain B6;129P2-Ptgs1 tm1 ) (28) and the ptghs-2 gene (COX-2, strain B6;129P2-Ptgs2 tm1 ) (38) were purchased from Taconic (Germantown, NY). COX-1/2 double knockout mice are not viable.(31) Age-matched mice from congenic strains (B6;129p2) were used as wild type controls. Mice genotypes were confirmed by PCR on DNA isolated from tail samples using Qiagen Dneasy kit (Qiagen Inc, Stamford, CA) as per manufactures instructions. Gene-specific primers: COX1: Prostacyclin (PGI 2 ) and thromboxane (TXA 2 ) have a relatively short half life in-vivo before they are converted to the biologically inactive 6-k-PGF1 and thromboxane-B 2 (TXB 2 ). Both analytes were measured by commercially available competitive ELISA kits in accordance with manufacturers instructions (Oxford Biomedical Research, MI). Extraction procedure was identical for 6-k-PGF1 and TXB 2 . Briefly, blood was collected by cardiac puncture, injected into heparinized tubes, centrifuged and plasma stored at 4 o C. Urine was collected over 24hr using metabolic cages and stored at 4 o C prior to analysis. Urine and plasma 6-k-PGF1 and plasma TXB 2 were isolated using SEP-PAK C-18 cartridges (Applied Separations, Allentown PA). Plasma was diluted with methanol to a final concentration of 15% and applied to a SEP-PAK C-18 cartridge that had been pre-equilibrated with 2ml Methanol and 2ml H 2 O at 1ml/min flow rate. After application of the plasma sample cartridges were washed with 2ml 15% methanol and 2ml petroleum ether at 1ml/min. 6-k-PGF1 and TXB 2 were eluted from the column with 2ml methyl formate at 1ml/min. Eluent was dried down by centrifugal evaporation and re-suspended in extraction buffer supplied within ELISA kits (Oxford Biomedical Research, MI). Urine 2,3-dinor-6-k-prostaglandin F1 levels 2,3-dinor-6-k-prostaglandin F1 (2,3-dinor-6-k-PGF1 ) is a stable oxidation metabolite of 6-k-PGF1 and levels have previously been used to quantitate systemic PGI 2 biosynthesis in mice and humans. (4, 43) In contrast, urine 6-k-PGF1 is predominantly a marker of renal COX-2 activity. Urine was collected for 7d and 2,3-dinor-6-k-PGF1 was extracted by a selective twostep solid-phase extraction as described previously.(44) 2,3-dinor-6-k-PGF1 was quantitated by a competitive ELISA for 2,3-dinor-6-k-PGF1 and 6-k-PGF1 (Assay Designs, MI) as per manufacturers instructions. Briefly, urine was first acidified with 0.1M HCl to pH 3.0 using a mini lab low volume pH meter (IQ scientific, CA) before incubation over night at room temperature. Spe-ed™ C-1 Methyl silica 500mg/6ml mini columns (Applied Separations, PA) were equilibrated with 5ml methanol and 5ml H 2 O at 2ml/min. Acidified urine was applied to the column at 0.5ml/min and the column was washed with 5ml H 2 O and 5ml n-hexane at 1ml/min. 2,3-dinor-6-k-PGF1 was eluted with 5ml diethyl ether:n hexane (85:15, v/v). Eluent was resuspended in prostanoid free urine (see below for preparation of prostanoid free urine) and pH altered to 10 with 0.1M sodium hydroxide and incubated for 1hr. Spe-ed™ C-1 Methyl silica 500mg/6ml mini columns were equilibrated as before and sample was applied at 0.5ml/min. Column was washed as before and 2,3-dinor-6-k-PGF1 was eluted with 5ml chloroform at 1ml/min, centrifugal evaporated and re-suspended in extraction buffer supplied in urine 2,3-dinor-6-k-PGF1 assay kit. Prostanoid free urine is prepared by adding activated charcoal to pooled urine from unadulterated B6129P2 mice (5% w/v) and stirred for 1hr. After centrifugation at 3000xg for 15 minutes supernatant was taken and assayed for 2,3-dinor-6-k-PGF1 and 6-k-PGF1 .
Determination of in-vivo
Cyclooxygenase activity inhibition using the COX-2 inhibitor NS398 and COX-1 inhibitor SC560 NS398 (N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) (Cayman Chemical, MI) is marketed as a selective COX-2 inhibitor (IC 50 COX-2=3.8 NM) but it can, at high doses, inhibit COX-1 activity (IC 50 COX-1>100Nm).(40) Titration of NS398 to selectively inhibit COX-2 in-vivo with minimal effect on COX-1 was determined by measurement of serum TXB 2 and 6-k-PGF1 and urine 6-k-PGF1 levels 24hr following IP administration of 1-10mg/ml NS398 or DMSO vehicle control in B6;129P2 wild type mice (Taconic, Germantown, NY). Urine 6-k-PGF1 is predominantly a marker of COX-2 activity whereas serum TXB 2 is representative of COX-1 activity. 2mg/kg NS398 was chosen to selectively inhibit COX-2 activity. Please see below for results. To determine the duration of inhibition 2mg/kg NS398 was given IP to B6;129P2 mice and 24hr urine 6-k-PGF1 levels were determined 0-72hr thereafter. To confirm that 2mg/kg NS398 was COX-2 specific COX-1 respectively) (Taconic, Germantown, NY) were given 2mg/kg NS398 IP and 24hr urine 6-k-PGF1 levels were determined.
SC560
(5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole) (Cayman Chemical, MI) is marketed as a selective COX-1 inhibitor (COX-1 IC 50 is 9nM), but it can, at high doses, inhibit COX-2 activity (COX-2 IC 50 is 6.3 NM).(49) Titration of SC560 to selectively inhibit COX-1 in-vivo with minimal effect on COX-2 was determined by measurement of serum TXB 2 and urine 6-k-PGF1 levels 24hr following IP administration of 10-80mg/ml SC560 or DMSO vehicle control in B6129P2 wild type mice. Urine 6-k-PGF1 is predominantly a marker of COX-2 activity whereas serum TXB 2 is representative of COX-1 activity. 20mg/kg SC560 was chosen to selectively inhibit COX-1 activity. Please see below for results. To determine the duration of inhibition 20mg/kg SC560 was given IP to B6129P2 mice and plasma TXB 2 was determined 0-72hr thereafter. To confirm that 20mg/kg SC560 was COX-1 specific COX-1 -/-and COX-2 -/-gene knockout mice were given 20mg/kg SC560 IP and plasma TXB 2 was quantitated. ) mice were subjected to either sham or PVL surgery as described above. In wild type mice abdominal aortic flow, splenic pulp pressure and plasma 6-k-PGF1 and TXB 2 levels were determined 1, 2, 4 and 7 days following sham or PVL (n=5 per group). In addition, 7d PVL and sham wild type mice were analyzed for 7d urine 2,3-dinor-6-k-PGF1 levels. In COX-1 -/-and COX-2 -/-mice abdominal aortic flow, splenic pulp pressure and 7d urine 2,3-dinor-6-k-PGF1 were determined 7d following sham or PVL surgery (n=5 per group).
Effects
Effects of pharmacological COX inhibition in wild type and COX isoform gene knockout mice on PGI 2 biosynthesis and portal hemodynamics
To determine the effects of COX-1 or COX-2 selective inhibitors on PGI 2 biosynthesis and portal hemodynamics following PVL wild type mice (B6;129P2) were treated with either 2 or 10mg/kg NS398 or 20 or 80mg/kg SC560 12hr prior to PVL or sham surgery. Both NS398 and SC560 have previously been used as COX selective inhibitors in the rat PVL model of PHT. (1) The two doses will show the effects of each compound when given at selective and non-isoform selective doses. After surgery NS398 was given daily whereas SC560 was given every 48hr. Urine was collected throughout and stored at 4 o C. 7 days following surgery abdominal aortic flow, splenic pulp pressure and 7d urine 2,3-dinor-6-k-PGF1 were determined. To determine the effect of pharmacological COX inhibition in COX isoform gene knockout mice COX-1 -/-and COX-2 -/-mice were given 2mg/ml NS398 or 20mg/kg SC560 IP 12 hr pre and post PVL or sham. After surgery NS398 was given daily whereas SC560 was given every 48hr. Urine was collected throughout and stored at 4 o C. On day 7 post PVL or sham abdominal aortic flow, splenic pulp pressure and 7d urine 2,3-dinor-6-k-PGF1 were determined.
Statistics
The data shown are means±S.E., with 5 animals per experimental group. Statistical significance was estimated using one-way ANOVA statistical analysis. A value of p<0.05 was considered significant. Wild type mice: In B6;129P2 wild type mice portal hemodynamics and PGI 2 biosynthesis were significantly increased following PVL when compared to sham operated controls. The abdominal aortic flow increased steadily 1 and 2 days following PVL but was not significantly different from shams. After 4 and 7d the abdominal aortic flow was significantly raised 23.5 and 58.8% respectively in PVL treated mice when compared to sham operated controls (figure 2a). The splenic pulp pressure progressively increased immediately following PVL and was elevated 64.2, 189.3, 266.3 and 281.5% 1, 2, 4 and 7d post PVL respectively when compared to sham operated controls (figure 2b). To determine PGI 2 biosynthesis plasma 6-k-PGF1 and urine 2,3-dinor-6-k-PGF1 were quantitated. PGI 2 rapidly converts to the stable and biologically inert 6-k-PGF1 and after oxidation to 2, 3-dinor-6-kPGF1 is excreted in the urine. 2,3-dinor-6-k-PGF1 and plasma 6-k-PGF1 levels have previously been used to quantitate systemic PGI 2 biosynthesis in mice and humans.(4, 43) Plasma 6-k-PGF1 was increased 2 fold 2 days after PVL and was maximally increased by 2.5 fold after 7 days when compared to shams (figure 2c). Correspondingly, 7d urine 2, 3-dinor-6-k-PGF1 excretion was significantly increased 336% following PVL when compared to shams (figure 2c). In comparison, plasma level of thromboxane B 2 , was not altered following PVL. Thromboxane B 2 is the stable in-vivo hydrolyzed product of thromboxane which is the unstable and bioactive metabolic product coupled to COX-1 activity. Not at any time following surgery was plasma thromboxane B 2 level significantly different between sham and PVL mice (figure 2d). Wild type mice: Urine 6-k-PGF1 and plasma TxB 2 levels were dose dependently reduced by NS-398 and SC560 when compared to DMSO controls. NS398: Urine 6-k-PGF1 (marker of COX-2 activity) was reduced 41% by 2mg/kg NS398 and was maximally reduced 75.8% at 10mg/kg (figure 4a). Plasma TXB 2 (marker of COX-1 activity) was not altered at 1-4mg/kg but was reduced 75.1% by 10mg/ml NS398 respectively (figure 4a). From this data, 2mg/kg NS398 was determined as a COX-2 specific inhibitory dose. To determine the length of inhibition 2mg/kg NS398 was given to B6;129P2 mice and 24hr urine 6-k-PGF1 levels were determined for 72hr. 2mg/kg NS398 reduced urine 6-k-PGF1 24 hr following administration. After 24hr levels were not significantly different when compared to 0mg/ml DMSO vehicle control levels therefore it was administered daily (figure 4c).
RESULTS
Portal vein ligation increases PGI 2 biosynthesis and portal hemodynamics in wild type
COX-
SC560:
Plasma TxB 2 was reduced by 26% by 20mg/kg SC560 and was maximally reduced by 71.9% at 80mg/kg. In contrast, urine 6-k-PGF1 was not altered at 20mg/kg but was reduced 44% by 80mg/ml SC560 (figure 4b). To determine the length of inhibition 20mg/kg SC560 was given to B6;129P2 mice and plasma TXB 2 levels were determined every 24hr for 72hr thereafter 20mg/kg SC560 reduced plasma TxB 2 levels 26% and 23% 24 and 48hr respectively following IP administration. After 48 hr there was no difference when compared to 0mg/kg DMSO vehicle controls therefore it was administered every second day (figure 4d).
Hemodynamic measurements: No significant hemodynamic changes were observed following administration of either NS398 or SC560. Abdominal aortic flow and splenic pulp pressure trended downwards with NS398 and high dose of SC560 but were not significantly altered when compared to DMSO vehicle controls (data not shown).
COX-1 -/-
and COX-2 -/-mice: To confirm COX isoform selective inhibition 2mg/kg NS398 or 20mg/kg SC560 were given to COX-2 -/-and COX-1 -/-mice. 6-k-PGF1 and TXB 2 levels were determined in urine and plasma respectively. 2mg/kg NS398 reduced urine 6-k-PGF1 levels by 42.3% in COX-1 -/-mice but had no effect in COX-2 -/-gene deleted mice when compared to 0hr controls (Figure 4c ). Conversely, 20mg/kg SC560 had no effect on plasma TXB 2 levels in COX-1 -/-mice, whereas in COX-2 -/-mice plasma TXB 2 was reduced 45.1% (figure 4d)
Pharmacological inhibition of cyclooxygenase with NS398 and SC560 to prevent portal hypertension is dose dependant:
To determine the effectiveness of COX inhibitors to limit PGI 2 biosynthesis and the development of PHT wild type B6;129P2 mice were treated with 2 and 10mg/kg NS398 or 20 and 80mg/kg SC560 prior and following PVL or sham surgery.
Effect of NS398:
In DMSO treated vehicle controls abdominal aortic flow, splenic pulp pressure and 7d urine 2,3-dinor-6-k-PGF1 were significantly increased by 59, 279 and 336% respectively 7d following PVL when compared to 7d sham controls. These increases were not significantly altered by daily administration of 2mg/kg NS398 and remained increased by 70.6, 213 and 291% respectively. However, when NS398 was given at 10mg/kg, which is not COX-2 selective, abdominal aortic flow, splenic pulp pressure and 7d urine 2,3-dinor-6-k-PGF1 were not significantly increased in PVL mice when compared to either DMSO-shams or 10mg/kg NS398-shams (figure 5a-c). There were no differences in abdominal aortic flow or splenic pulp pressure amongst DMSO-shams, 2mg/kg NS398-shams and 10mg/kg NS398-shams.
Effect of SC560:
altered by daily administration of 20mg/kg SC560 and remained increased by 70, 132 and 160% respectively. However, when SC560 was given at 80mg/kg, which is not COX-1 selective, abdominal aortic flow, splenic pulp pressure and 7d urine 2,3-dinor-6-k-PGF1 were not significantly increased in PVL mice when compared to either DMSO-shams or 80mg/kg SC560-shams (figure 5d-f). There were no significant differences in abdominal aortic flow or splenic pulp pressure amongst DMSO-shams, 20mg/kg SC560-shams and 80mg/kg SC560-shams. mice: There were no significant differences in abdominal aortic flow, splenic pulp pressure or 2,3-dinor-6-k-PGF1 amongst 7d DMSO-shams, 2mg/kg NS398-shams and 20mg/kg SC560-shams. 7d following PVL surgery abdominal aortic flow, splenic pulp pressure and 2,3-dinor-6-k-PGF1 were increased 45, 70 and 295% respectively in PVL-DMSO mice when compared to 7d Sham-DMSO controls (figure 6a-c). 2mg/kg NS398 significantly reduced these increases, whereas 20mg SC560 did not. Abdominal aortic flow, splenic pulp pressure and 2,3-dinor-6-k-PGF1 were minimally increased 7, 14 and 9% respectively in 7d PVL-NS398 COX-1 -/-mice when compared to 7d sham-NS398 COX-1 -/-mice. In COX-1 -/-mice treated with 20mg/kg SC560 abdominal aortic flow, splenic pulp pressure and 2,3-dinor-6-k-PGF1 were increased 30, 58 and 265% respectively in 7d PVL-SC560 mice when compared to 7d Sham-SC560 mice (figure 6a-c).
COX targeted
COX-2
-/-mice: There were no significant differences in abdominal aortic flow, splenic pulp pressure or 2,3-dinor-6-k-PGF1 amongst 7d DMSO-shams, 2mg/kg NS398-shams and 20mg/kg SC560-shams. In contrast 7d urine 2,3-dinor-6-k-PGF1 was reduced 32.8% in 20mg/kg SC560-sham mice when compared to DMSO-sham controls. 7d following PVL surgery abdominal aortic flow, splenic pulp pressure and 2,3-dinor-6-k-PGF1 were increased 35.3, 53 and 295% respectively in PVL-DMSO mice when compared to 7d Sham-DMSO controls (figure 6d-e). 2mg/kg NS398 did not significantly reduce these increases, whereas 20mg/kg SC560 significantly reduced any increase. Abdominal aortic flow, splenic pulp pressure and 2,3-dinor-6-k-PGF1 were increased 40, 32 and 254% respectively in 7d PVL-NS398 COX-2 -/-mice when compared to 7d sham-NS398 COX-2 -/-mice. In COX-2 -/-mice treated with 20mg/kg SC560 abdominal aortic flow and splenic pulp pressure were reduced 14 and 16% respectively whereas and 2,3-dinor-6-k-PGF1 was increased 36.4% in 7d PVL-SC560 mice when compared to 7d Sham-SC560 mice (figure 6d-f).
DISCUSSION
To investigate the role of COX-isoforms in PGI 2 biosynthesis and PHT we utilized commercially available COX gene deficient mice and COX isoform selective inhibitors and documented changes in PGI 2 biosynthesis and the development of PHT following portal vein ligation (PVL). We found no COX isoform predominance in PGI 2 biosynthesis or PHT development, which argues that COX selective inhibitors would not be beneficial in the treatment of PHT. PGI 2 biosynthesis, abdominal aortic flow and splenic pulp pressure were increased in COX-1 -/-and COX-2 -/-mice and in wild type mice treated with COX-1 (20mg/kg SC560) or COX-2 (2mg/kg NS398) selective inhibitors. Whereas, when both COX isoforms were inhibited PGI 2 biosynthesis was reduced, thus preventing vasodilatation and the formation of a hyper-dynamic circulation. This prevents the development of PHT in the PVL model because in the absence of hyperemia portal systemic shunting negates the resistance caused by the mechanical stenosis.
There are a couple of reasons why no COX isoform predominates in this model. 1) COX-1 and COX-2 coexist in the vasculature and may be compensating for each other. Typical of most studies using gene knock out mice, data must be interpreted with caution as redundant and/or compensatory mechanisms can appear. Indeed this may explain why PGI 2 levels were not reduced in COX-2 -/-mice until treated with the COX-1 inhibitor SC560. Moreover, PGH 2 can be synthesized in platelets via COX-1 and transferred to endothelial cells and converted to PGI 2 . (34) 2) COX heterodimers are resistant to COX isoform selective inhibition.(62) In COX gene deficient mice heterodimers cannot form but PGI 2 biosynthesis was unaltered, showing that both COX-1 and COX-2 homodimers can mediate PGI 2 biosynthesis in both basal and elevated PGI 2 biosynthesis. These findings argue that additional targets, down stream of COX, need to be considered and investigated. Alternative targets for PGI 2 include: 1) inhibition of prostaglandin I 2 synthase and 2) antagonism of prostacyclin signaling.
The synthesis of stable PGH 2 analogues has generated a potent inhibitor for PGIS which has been used experimentally to investigate the role of PGI 2 in multiple pathophysiological events. (6, 21 , 41) To our knowledge, PGIS inhibitors have not been used to reduce PGI 2 biosynthesis and PHT in-vivo. Following synthesis, PGI 2 activates the G protein coupled cell surface prostacyclin receptor (IP). Activation of IP receptors stimulates adenylyl cyclase, leading to increased cAMP, vasodilation, inhibition of cell proliferation and release of imflammatory mediators.(58) Alternatively, PGI 2 is also capable of activating peroxisome proliferator activated receptor (PPAR )(30), which is reported to have anti-imflammatory properties.(29) Targeted gene deficient mice for both IP and PPAR have been generated.(8, 53) To our knowledge, the development of PHT has not been investigated in these animals. With that said these mice have multiple pathologies associated with a lack of normal PGI 2 signaling and as such any investigation would be problematic. Specifically, deletion of IP elevates blood pressure, modulates vascular remodeling and was found to promote atherosclerosis in mice via impaired activation of neutrophils and platelets. (2, 8, 13 , 25, 52) COX isoforms are also important in regulating renal function. In the kidney PGIS and IP are mainly found in the mesangial cells and afferent arterial endothelial cells.(26, 39) PGI 2 regulates blood flow and therefore filtration rate of the kidney.(3, 17) In PGI 2 deficient mice progressive morphological abnormalities develop in the kidney and mice have increased blood pressure and elevated plasma urea, nitrogen and creatinine levels. However these abnormalities have not been reported in IP deficient mice.(61) In this study we found that urine output is significantly reduced immediately following PVL in wild type and COX-1 and -2 -/-mice. After which urine output increases but does not exceed pre-surgical levels (data not shown). This is counter to an increase in PGI 2 increasing renal output. The initial reduction is probably linked to the temporary drop in systemic blood flow that follows PVL. Therefore, serious consideration is required to evaluate the renal complications associated with PGI 2 inhibition. Such an evaluation was not included in this study and would need to be covered separately. Inasmuch, the interaction between COX and nitric oxide synthase (NOS) has also not been focused on in this study. The family of NOS enzymes also produces a potent vasodilator (NO), which has been even more significantly linked with the development of PHT.(37, 54) Data suggests that NOS and COX are significantly linked and both influence and compensate for one another.(12, 37) Salvemini and coworkers initially demonstrated that enhanced release of prostaglandins was nearly entirely driven by NO. (45) Subsequently, additional mechanistic studies have investigated how NO switches on/off the COX pathway have shown pathways through which NO modulates prostaglandin production. We did not study this NO/COX crosstalk specifically but we did observe that eNOS mRNA was significantly up regulated in both arteriolar and venous tissues of COX-1 -/-mice but not COX-2 -/-mice (data not shown). Moreover, preliminary studies investigating PGI 2 in eNOS -/-mice show that plasma 6-k-PGF1 was not increased following PVL (data not shown). Consequently NO/COX crosstalk is highly pertinent in both normal and disease pathophysiology and needs to be considered when considering the potential of PGI 2 inhibition in any PHT treatment paradigm.
In conclusion, PGI 2 is very important to the development of systemic hyperemia and elevated portal pressure in the PVL model of pre-hepatic PHT. Moreover, PGI 2 biosynthesis is not COX-1 or COX-2 dependant. These findings direct further research towards other aspects of PHT vasculopathy. Targeting of PGI 2 directly via either its synthesis or signaling might be an improvement, but may have the same caveats as COX-2 inhibitors and may also affect renal function. Inhibition of PGI 2 should not interfere with the gastric protective PGE 2 but cardiovascular complication risk may increase. Recent studies have shown that increased PGI 2 in the rat PVL model corresponds with a decreased in-vivo platelet activity resulting in reduced laser induced thrombus formation. (14) While this protects against cardiovascular accidents it exacerbates variceal bleeding. Therefore, not only would PGI 2 inhibition reduce splanchnic hyperemia it would also reduce bleeding complications associated with portal hypertension. Any increased cardiovascular risk may be reduced by utilizing a multi target approach. Targeted inhibition of both thromboxane and PGI 2 synthesis would be one option. In addition to PGIS inhibitors thromboxane synthase inhibitors have been identified (U44069) as have IP antagonists.(9, 21) Alternatively, given the resistance of COX heterodimers to isoform selective inhibitors and the discovery of COX-1 inhibitors that do not induce gastrointestinal complications it may be possible to reduce systemic thromboxane via COX-1 inhibition without disturbing PGE 2 gastrointestinal protection. However, evidence in this manuscript and others suggests that COX-1 inhibitors are not neutral under pathologic conditions.(1) Nevertheless, given the renewed interest in COX and prostanoids in disease pathology additional studies, to better understand the role of PGI 2 in PHT, are warranted and relevant in order to develop new treatments to reduce PHT and its associated mortality and morbidity. In particular, a better understanding of PGI 2 , trigger, signaling and NO crosstalk within PHT models is needed and may bare fruit for novel targets for clinical therapy. 
LEGENDS Figure 1. Prostaglandin synthesis pathway
(a) Cyclooxygenase is a heme-containing glycoprotein and is a key enzyme in prostanoid biosynthesis by catalyzing the conversion of arachidonic acid to PGH 2 . Subsequently, PGH 2 is converted to active prostanoids via secondary prostanoid synthases. Prostacyclin has a half life of approx 1hr before inactivation via a non-enzymatic hydration to form 6-keto-PGF1 . (b) 6-keto-PGF1S is further metabolized in urine to form the 2,3-dinor derivative 2,3d-6k-PGFTS. Pre-hepatic PHT was induced in B6;129P2 wild type mice by PVL. Control mice received a sham operation. 1-7d post surgery splenic pulp pressure and abdominal aortic flow were measured and plasma was analyzed for metabolites of prostacyclin (6-k-PGF1 ) and thromboxane (TXB 2 ). In addition total urine output from the 7d sham and PVL mice was To confirm the selectivity of commercially available COX inhibitors B6;129P2 or COX gene knockout mice were given either the COX-2 inhibitor NS398 (a+c) or the COX-1 inhibitor SC560 (b+d). In-vivo COX inhibition was determined by quantitating plasma TXB 2 (marker of COX-1 activity) or urine 6-k-PGF1 (marker of COX-2 activity) levels. (a) 2mg/kg NS398 dose dependently reduced urine 6-k-PGF1 levels (dark bars) with no significant change in plasma TXB 2 levels (open bars). At 10mg/kg NS398 decreased plasma TXB 2 levels also. (b) 20mg/kg SC560 reduced plasma TXB 2 levels (open bars) with no significant change in urine 6-k-PGF1 (dark bars). 80mg/kg SC560 decreased plasma TXB 2 levels also. 2mg/kg NS398 and 20mg/kg SC560 were determined to achieve selective inhibition of COX-2 and COX-1 isoforms respectively. B6;129P2 mice were given either DMSO (vehicle control) 2-10mg/kg/day NS-398 or 20-80mg/kg SC560 IP 24hr prior to partial PVL or sham surgery. DMSO and 2-10mg/kg NS398 were given daily thereafter for 7d, SC560 was given at 20-80mg/kg every 48hr thereafter for 7 days. During this time total urine output was collected. After 7d the abdominal aortic flow (a+d) and splenic pulp pressure (b+e) were measured and the urine was analyzed for the prostacyclin metabolite 2,3-dinor-6-k-PGF1 (c+f). Figures above show data for 7d sham-DMSO as there was no effect of 2-10mg/kg NS398 or 20-80mg/kg SC560 in shams. (a-c) Abdominal aortic flow, splenic pulp pressure and 7d urine 2,3-dinor-6-k-PGF1 were increased 7d following PVL (dark bars) when compared to 7d shams (open bars). Treatment with 2mg/kg NS398 (diagonal bars) did not prevent these increases, whereas treatment with 10mg/kg NS398 (diamond bars) significantly reduced all three. (d-f) Similarly, abdominal aortic flow, splenic pulp pressure and urine 7d 2,3-dinor-6-k-PGF1 remained elevated in 7d PVL mice treated with the low, 20mg/kg, dose of SC560 (diagonal bars) when compared to PVL-DMSO and sham-DMSO controls. Whereas, 80mg/kg SC560 (diamond bars) prevented an increase in abdominal aortic flow, splenic pulp pressure and 2,3-dinor-6-k-PGF1 . Data represents mean±S.E n=5 per group. (a) Cyclooxygenase is a heme-containing glycoprotein and is a key enzyme in prostanoid biosynthesis by catalyzing the conversion of arachidonic acid to PGH 2 . Subsequently, PGH 2 is converted to active prostanoids via secondary prostanoid synthases. Prostacyclin has a half life of approx 1hr before inactivation via a non-enzymatic hydration to form 6-keto-PGF1α. (b) 6-keto-PGF1α is further metabolized in urine to form the 2,3-dinor derivative 2,3d-6k-PGF1α. Pre-hepatic PHT was induced in B6;129P2 wild type mice by PVL. Control mice received a sham operation. 1-7d post surgery splenic pulp pressure and abdominal aortic flow were measured and plasma was analyzed for metabolites of prostacyclin (6-k-PGF1α) and thromboxane (TXB 2 ). In addition total urine output from the 7d sham and PVL mice was collected and measured for 2,3-dinor-6-k-PGF1α (β-oxidative metabolite of 6-k-PGF1α). ) (d-f) mice were subjected to either a partial PVL or sham surgery and urine was collected for 7days. After this time the abdominal aortic flow and splenic pulp pressure were measured and the urine was analyzed for the prostacyclin metabolite 2,3-dinor-6-k-PGF1α. Following PVL abdominal aortic flow (a+d), splenic pulp pressure (b+e) and urine 7d 2,3-dinor-6-k-PGF1α (c+f) were all significantly increased 7d following PVL when compared to sham controls. Data represents mean±S.E, n=5 per group. To confirm the selectivity of commercially available COX inhibitors B6;129P2 or COX gene knockout mice were given either the COX-2 inhibitor NS398 (a+c) or the COX-1 inhibitor SC560 (b+d). In-vivo COX inhibition was determined by quantitating plasma TXB 2 (marker of COX-1 activity) or urine 6-k-PGF1α (marker of COX-2 activity) levels. (a) 2mg/kg NS398 dose dependently reduced urine 6-k-PGF1α levels (dark bars) with no significant change in plasma TXB 2 levels (open bars). At 10mg/kg NS398 decreased plasma TXB 2 levels also. (b) 20mg/kg SC560 reduced plasma TXB 2 levels (open bars) with no significant change in urine 6-k-PGF1α (dark bars). 80mg/kg SC560 decreased plasma TXB 2 levels also. 2mg/kg NS398 and 20mg/kg SC560 were determined to achieve selective inhibition of COX-2 and COX-1 isoforms respectively. ) (d-f) mice were given either DMSO (vehicle control) 2mg/kg/day NS-398 or 20mg/kg SC560 IP prior to and following partial PVL or sham surgery. DMSO and 2mg/kg NS398 was given daily for 7d, SC560 was given at 20mg/kg every 48hr for 7d. During this time total urine output was collected. After 7d the abdominal aortic flow (a+d) and splenic pulp pressure (b+e) were measured and the urine was analyzed for the prostacyclin metabolite 2,3-dinor-6-k-PGF1α. Figures above show data for 7d sham-DMSO as there was minimal effect of 2mg/kg NS398 or 20mg/kg SC560 in shams. (a-f) In both COX-1 -/-and COX-2 -/-mice abdominal aortic flow, splenic pulp pressure and 7d urine 2,3-dinor-6-k-PGF1α were increased 7d following PVL (dark bars) when compared to 7d shams (open bars). Treatment with 2mg/kg NS398 (diagonal bars) prevented this increase in 7d PVL-COX-1 -/-mice, whereas treatment with 20mg/kg SC560 had no effect. In contrast, abdominal aortic flow, splenic pulp pressure and urine 7d 2,3-dinor-6-k-PGF1α were significantly reduced in 7d PVL-COX-2 -/-mice treated with 20mg/kg SC560 but remained elevated in mice treated with 2mg/kg NS398. Data represents mean±S.E n=5 per group.
